A Phase III trial of Sanofi's isatuximab’s has proven successful, showing that the drug achieved the primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.